Skip to main content

Home/ PharmaMics/ Group items tagged oncology

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
ramchintamaneni

Biosimilars in oncology: immunogenicity and extrapolation at ESMO 2019 - 0 views

www.pharmaceutical-technology.com/...o-2019-biosimilars-in-oncology

#esmo2019 #esmocongress #esmoconference #esmocongress2019 #oncology #biosimilar #pharmacynews #pharmaindustry

shared by ramchintamaneni on 15 Oct 19 - No Cached
  • ramchintamaneni on 15 Oct 19
     
    Biosimilars in oncology: Less than 50% of oncologists were prescribing biosimilars, primarily due to concerns regarding immunogenicity and extrapolation.
Hellan George

Forging a path in specialty care - PMLiVE - 0 views

www.pmlive.com/..._path_in_specialty_care_932953

Takeda interview oncology gastroenterology vaccines specialty care

shared by Hellan George on 22 Feb 16 - No Cached
  • Hellan George on 22 Feb 16
     
    Takeda's Marc Princen on the company's plans to build a reputation in oncology, gastroenterology and vaccine
Alex Parker

Novartis reshapes business by signing deals with GSK, Eli Lilly - 2 views

manufacturing.pharmaceutical-business-review.com/...h-gsk-eli-lilly-220414-4218360

drugs pharmacy New

shared by Alex Parker on 23 Apr 14 - No Cached
  • Alex Parker on 23 Apr 14
     
    PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.
ramchintamaneni

ESMO: Kisqali shows superior overall survival in breast cancer - 0 views

www.clinicaltrialsarena.com/...esmo-novartis-kisqali

#esmo2019 #esmocongress #esmoconference #esmocongress2019 #drugdevelopment #medicalnews #medicalindustry

shared by ramchintamaneni on 07 Oct 19 - No Cached
  • ramchintamaneni on 07 Oct 19
     
    Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.
ramchintamaneni

Bristol-Myers Squibb: Phase III CheckMate-227, Part 1 study ESMO 2019 - 0 views

www.pharmaceutical-technology.com/...esmo-2019-bristol-myers-squibb

#esmo2019 #esmocongress #esmoconference #esmocongress2019 #bristolmyerssquibb #bms #NSCLC #cancertreatment

shared by ramchintamaneni on 21 Oct 19 - No Cached
  • ramchintamaneni on 21 Oct 19
     
    Final data from BMS's Phase III CheckMate-227, Part 1 study was presented at the European Society of Medical Oncology conference in September.
Alex Parker

Novartis announces acquisition of CoStim Pharmaceuticals - 0 views

processandproduction.pharmaceutical-business-review.com/...pharmaceuticals-180214-4179543

drugs pharmacy

shared by Alex Parker on 19 Feb 14 - No Cached
  • Alex Parker on 19 Feb 14
     
    Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.
Alex Parker

RainTree launches new cloud-based analytics portal for pharmaceutical industry - 1 views

itsoftware.pharmaceutical-business-review.com/...utical-industry-160414-4215651

drugs pharmacy

shared by Alex Parker on 17 Apr 14 - No Cached
  • Alex Parker on 17 Apr 14
     
    RainTree Oncology Services and Information Builders have launched OncoExplorer, a new cloud-based analytics portal that offers unprecedented decision-support capabilities to pharmaceutical companies.
1 - 7 of 7
Showing 20▼ items per page